Ariad Reports in line 4Q Loss - Analyst Blog
February 27 2013 - 5:10AM
Zacks
Ariad Pharmaceuticals,
Inc. (ARIA) reported fourth quarter loss of 36 cents per
share, compared with the year-ago loss of 23 cents per share. The
Zacks Consensus Estimate for the fourth quarter was in line with
the company’s report.
The company’s fourth quarter 2012
revenues decreased 5.2% to $0.07 million much below the Zacks
Consensus Estimate of $1 million.
Research and development (R&D)
expenses climbed 52.5% to $37.6 million in the final quarter of
2012. The increase was attributable to the company’s efforts to
develop its pipeline. General and administrative (G&A) expenses
jumped 227.1% to $22.9 million in the fourth quarter of 2012. The
massive increase was primarily attributable to the expenses
incurred by the company in preparation of the launch of
Iclusig.
We note that in Dec 2012, the US
Food and Drug Administration (FDA) granted accelerated approval to
Iclusig (ponatinib) for use in heavily pretreated patients,
suffering from resistant and refractory chronic myeloid leukemia
(CML) and Philadelphia chromosome-positive acute lymphoblastic
leukemia (Ph+ ALL).
Full year 2012 loss was $1.24 per
share, wider than the year-ago loss of $0.58 per share, but
narrower than the Zacks Consensus Estimate of a loss of $1.33 per
share. Full year revenues came in at approximately $0.6 million
compared with $25.3 million in 2011. The Zacks Consensus Estimate
for the full year was $1 million.
2013 Guidance
Apart from releasing its financial
results, Ariad Pharma also provided guidance for 2013. Ariad Pharma
expects R&D expenses in the range of $238−$248 million ($144.7
million in 2012). The guidance reflects the increase in development
expenditure related to Iclusig and pipeline candidates including
AP26113, which is being developed for the treatment of non-small
cell lung cancer and other tumors.
Ariad Pharma expects G&A
expenses in the range of $108−$116 million ($60.9 million in 2012).
The increased guidance reflects the company’s efforts to expand
further.
Our Take
We are pleased by the U.S. approval
of Iclusig. Ariad Pharma is looking to get Iclusig approved in
additional markets. The drug is under accelerated assessment review
in the EU for treating adults with resistant or intolerant CML or
Ph+ ALL.
Ariad Pharma expects Iclusig to be
approved in the EU in the third quarter of 2013. The company
expects to seek Iclusig’s approval in Canada, Switzerland and
Australia in the second half of 2013. Japanese approval of the drug
is expected to be sought in Japan in mid-2014. Ariad pharma also
intends to expand the label of Iclusig into additional indications
such as gastrointestinal stromal tumors, molecular lung cancers,
acute myeloid leukemia and other solid tumors.
Ariad Pharma currently carries a
Zacks Rank #3 (Hold). Pharma stocks, which currently appear to be
more attractive, include United Therapeutics
Corporation (UTHR), Lannett Company, Inc.
(LCI) and SIGA Technologies, Inc. (SIGA). All
three companies carry a Zacks Rank #1 (Strong Buy).
ARIAD PHARMA (ARIA): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
SIGA TECH INC (SIGA): Free Stock Analysis Report
UTD THERAPEUTIC (UTHR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
London Clubs (AMEX:LCI)
Historical Stock Chart
From Jun 2024 to Jul 2024
London Clubs (AMEX:LCI)
Historical Stock Chart
From Jul 2023 to Jul 2024